Crizotinib in ALK-positive lung cancer

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages 962-963

  Girard, Nicolas ^a  

^a LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ALK GENE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84866942107     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70375-3     Document Type: Letter

References (10)

1. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, published online Sept 4. http://dx.doi.org/10.1016/S1470-2045(12)70344-3.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Pao W, Girard N New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
5. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
6. Pao W, Chmielecki J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10:760-774.
7. Otterson GA, Riely GJ, Shaw AT, et al. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7600.
8. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
9. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
10. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.